Citations

Clear

2960 citation(s) found for "Kim, P".

Donor types and outcomes of transplantation in myelofibrosis: a CIBMTR study
Jain, Tania , Estrada‐Merly, Noel, Salas, María Queralt , Kim, Soyoung , DeVos, Jakob D. , Chen, Min , Fang, Xi , Kumar, Rajat , Elmariah, Hany , Aljurf, Mahmoud , Badar, Talha , Ballen, Karen K. , Bredeson, Christopher , DeFilipp, Zachariah , Farhadfar, Nosha , Farhan, Shatha , Gandhi, Arpita , Ganguly, Siddhartha , Hamilton, Betty K. , Inamoto, Yoshihiro , Jamy, Omer , Kharfan‐Dabaja, Mohamed A. , Krem, Maxwell M. , Lad, Deepesh , Malone, Adriana K. , Pawarode, Attaphol , Poel, Marjolein van der , Rizzieri, David A. , Savoie, Mary Lynn , Seo, Sachiko , Solh, Melhem , Üstün, Celalettin , Verdonck, Leo F. , Wirk, Baldeep , Bejanyan, Nelli , Jones, Richard J., Nakamura, Ryotaro , Scott, Bart L. , Saber, Wael , Gupta, Vikas , Salas, M Queralt , Elmariah, Hany , Bacher, Ulrike , Badar, Talha , Bhatt, Vijaya Raj , DeFilipp, Zachariah , Dholaria, Bhagirathbhai R , Farhan, Shatha , Hamad, Nada , Hamilton, Betty K , Inamoto, Yoshihiro , Jamy, Omer , Juckett, Mark , Kharfan-Dabaja, Mohamed A , Krem, Maxwell M , Al Malki, Monzr M , Malone, Adriana K , Murthy, Hemant S , Patel, Sagar , Perales, Miguel-Angel , Ringden, Olov , Rovó, Alicia , Savani, Bipin N , Savoie, Mary Lynn , Seo, Sachiko , Ustun, Celalettin , Verdonck, Leo F , Bejanyan, Nelli , Nishihori, Taiga , Nakamura, Ryotaro , Scott, Bart , Gupta, Vikas , Jain, Tania , Kim, Soyoung , Andrade‐Campos, Marcio , Agrawal, Vaibhav , Badawy, Sherif M. , Beitinjaneh, Amer , Bhatt, Vijaya Raj , Dholaria, Bhagirathbhai , Gergis, Usama , Grunwald, Michael R. , Hamad, Nada , Iqbal, Madiha , Liesveld, Jane L. , Malki, Monzr M. Al , Murthy, Hemant S. , Ortí, Guillermo, Patel, Sagar S. , Perales, Miguel‐Angel , Ringdén, Olle , Savani, Bipin N. , Wingard, John R. , Nishihori, Taiga , Oran, Betül

Mayo Clinic

Blood Advances | June 25, 2024 | Volume: 8 | Issue: 16 | Pages: 4281-4293

10.1182/bloodadvances.2024013451 | PMID 38916866 Get It

Abstract We evaluate the impact of donor types on outcomes of hematopoietic cell transplantation (HCT) in myelofibrosis, using the Center for International Blood and Marrow Transplant Research registry data for HCTs done between 2013 and 2019. In all 1597 patients, the use of haploidentical donors increased from 3% in 2013 to 19% in 2019. In study-eligible 1032 patients who received peripheral blood grafts for chronic-phase myelofibrosis, 38% of recipients of haploidentical HCT were non-White/Caucasian. Matched sibling donor (MSD)–HCTs were associated with superior overall survival (OS) in the first 3 months (haploidentical hazard ratio [HR], 5.80 [95% confidence interval (CI), 2.52-13.35]; matched unrelated (MUD) HR, 4.50 [95% CI, 2.24-9.03]; mismatched unrelated HR, 5.13 [95% CI, 1.44-18.31]; P < .001). This difference in OS aligns with lower graft failure with MSD (haploidentical HR, 6.11 [95% CI, 2.98-12.54]; matched unrelated HR, 2.33 [95% CI, 1.20-4.51]; mismatched unrelated HR, 1.82 [95% CI, 0.58-5.72]). There was no significant difference in OS among haploidentical, MUD, and mismatched unrelated donor HCTs in the first 3 months. Donor type was not associated with differences in OS beyond 3 months after HCT, relapse, disease-free survival, or OS among patients who underwent HCT within 24 months of diagnosis. Patients who experienced graft failure had more advanced disease and commonly used nonmyeloablative conditioning. Although MSD-HCTs were superior, there is no significant difference in HCT outcomes from haploidentical and MUDs. These results establish haploidentical HCT with posttransplantation cyclophosphamide as a viable option in myelofibrosis, especially for ethnic minorities underrepresented in the donor registries.
Diagnostic testing and laboratory equity in clinical microbiology
Larkin, Paige M. K. , Theel, Elitza S. , Culbreath, Karissa , Garner, Omai B. , Vassell, Shannon, Kim, Wes , She, Rosemary C. , Long, S. Wesley , Babady, N. Esther , Wesley Long, S , Babady, Esther , Kim, Wes

Mayo Clinic

Microbiology Spectrum | June 25, 2024 | Volume: 12 | Issue: 8 | Pages: No page available

10.1128/spectrum.01222-24 | PMID 38916359 Get It

Correlation analyses of radiographic progression‐free survival with clinical and health‐related quality of life outcomes in metastatic castration‐resistant prostate cancer: Analysis of the phase 3 VISION trial
Morris, Michael J. , Bono, Johann S. de , Wei, Xiao X. , Nordquist, Luke T., Koshkin, Vadim S. , Krause, Bernd J. , Herrmann, Ken, Vickers, Adrian D. , Mirante, Osvaldo, Ghouse, Ray, Fizazi, Karim , Koshkin, Vadim S , Tagawa, Scott T , Morris, Michael J , de Bono, Johann , Nagarajah, James , Sartor, Oliver , N., Kim , Rahbar, Kambiz , Tagawa, Scott T.

Mayo Clinic

Cancer | June 21, 2024 | Volume: 130 | Issue: 20 | Pages: 3426-3435

10.1002/cncr.35438 | PMID 39031642 Get It

AbstractBackground[177Lu]Lu–PSMA‐617 (177Lu‐PSMA‐617) plus protocol‐permitted standard of care (SOC) prolonged overall survival (OS) and radiographic progression‐free survival (rPFS) versus SOC in patients with prostate‐specific membrane antigen (PSMA)–positive metastatic castration‐resistant prostate cancer (mCRPC) in the phase 3 VISION study, in addition to beneficial effects on symptomatic skeletal events (SSEs) and health‐related quality of life (HRQOL).MethodsPost hoc analyses used the full analysis set from the VISION study (N = 831) overall and by randomized treatment arm (177Lu‐PSMA‐617 plus SOC, n = 551; SOC, n = 280). Correlations were determined between OS and rPFS and between rPFS or OS and time to SSE or to worsening HRQOL (Functional Assessment of Cancer Therapy–Prostate [FACT‐P] and 5‐level EQ‐5D [EQ‐5D‐5L]). Correlation analyses used an iterative multiple imputation copula‐based approach (correlation coefficients [rho] of <0.3 were defined as weak, ≥0.3 and <0.5 as mild, ≥0.5 and <0.7 as moderate, and ≥0.7 as strong).ResultsIn the overall population, rPFS correlated strongly with OS (rho, ≥0.7). Correlations between rPFS or OS and time to SSE without death were weak or mild. Time to worsening in the FACT‐P total score and emotional and physical well‐being domains correlated mildly or moderately with rPFS and moderately with OS. Correlation coefficients for time‐to‐worsening EQ‐5D‐5L scores were mild to moderate for both rPFS and OS. Correlation coefficients were similar between treatment arms.ConclusionsIn this analysis of the VISION study, rPFS correlated strongly with OS but not with time to SSE or worsening HRQOL. These findings require further investigation.
Riluzole for Degenerative Cervical Myelopathy
Pedro, Karlo M. , Badhiwala, Jetan H. , Ahn, Henry, Shaffrey, Christopher I. , Mummaneni, Praveen V. , Jacobs, W. Bradley , Riew, K. Daniel , Hilibrand, Alan S. , Kim, Kee D. , Fourney, Daryl R. , Santaguida, Carlo , Massicotte, Eric M. , Fehlings, Michael G. , Alvi, Mohammed Ali , Farhadi, H. Francis , Nassr, Ahmad , Arnold, Paul M. , Riew, Kiehyun Daniel , Kelly, Michael P. , Brodke, Darrel Scott , Vaccaro, Alexander R. , Wilson, Jason, Harrop, James Shields , Huang, Peng

Mayo Clinic

JAMA Network Open | June 21, 2024 | Volume: 7 | Issue: 6 | Pages: e2415643

10.1001/jamanetworkopen.2024.15643 | PMID 38904964 Get It

Importance The modified Japanese Orthopaedic Association (mJOA) scale is the most common scale used to represent outcomes of degenerative cervical myelopathy (DCM); however, it lacks consideration for neck pain scores and neglects the multidimensional aspect of recovery after surgery. Objective To use a global statistical approach that incorporates assessments of multiple outcomes to reassess the efficacy of riluzole in patients undergoing spinal surgery for DCM. Design, Setting, and Participants This was a secondary analysis of prespecified secondary end points within the Efficacy of Riluzole in Surgical Treatment for Cervical Spondylotic Myelopathy (CSM-PROTECT) trial, a multicenter, double-blind, phase 3 randomized clinical trial conducted from January 2012 to May 2017. Adult surgical patients with DCM with moderate to severe myelopathy (mJOA scale score of 8-14) were randomized to receive either riluzole or placebo. The present study was conducted from July to December 2023. Intervention Riluzole (50 mg twice daily) or placebo for a total of 6 weeks, including 2 weeks prior to surgery and 4 weeks following surgery. Main Outcomes and Measures The primary outcome measure was a difference in clinical improvement from baseline to 1-year follow-up, assessed using a global statistical test (GST). The 36-Item Short Form Health Survey Physical Component Score (SF-36 PCS), arm and neck pain numeric rating scale (NRS) scores, American Spinal Injury Association (ASIA) motor score, and Nurick grade were combined into a single summary statistic known as the global treatment effect (GTE). Results Overall, 290 patients (riluzole group, 141; placebo group, 149; mean [SD] age, 59 [10.1] years; 161 [56%] male) were included. Riluzole showed a significantly higher probability of global improvement compared with placebo at 1-year follow-up (GTE, 0.08; 95% CI, 0.00-0.16; P = .02). A similar favorable global response was seen at 35 days and 6 months (GTE for both, 0.07; 95% CI, −0.01 to 0.15; P = .04), although the results were not statistically significant. Riluzole-treated patients had at least a 54% likelihood of achieving better outcomes at 1 year compared with the placebo group. The ASIA motor score and neck and arm pain NRS combination at 1 year provided the best-fit parsimonious model for detecting a benefit of riluzole (GTE, 0.11; 95% CI, 0.02-0.16; P = .007). Conclusions and Relevance In this secondary analysis of the CSM-PROTECT trial using a global outcome technique, riluzole was associated with improved clinical outcomes in patients with DCM. The GST offered probability-based results capable of representing diverse outcome scales and should be considered in future studies assessing spine surgery outcomes.
Bicuspid Aortic Valve Disease with Early-Onset Complications: Characteristics and Aortic Outcomes
Selbst, Maximilian A. , Svetgoff, Megan L., Sabaté-Rotés, Anna , Backer, Julie De , Mosquera, Laura Muiño , Yetman, Anji T. , Bissell, Malenka M. , Andreassi, Maria Grazia , Foffa, Ilenia , Hui, Dawn S. , Caffarelli, Anthony, Kim, Yuli Y. , Guo, Dongchuan , Citro, Rodolfo , Marco, Margot De , Tretter, Justin T. , Morris, Shaine A. , Body, Simon C. , Prakash, Siddharth K. , Morris, Shaine A , Prakash, Siddharth K , Bissell, Malenka M , Body, Simon C , Citro, Rodolfo , De Backer, Julie F A , Kim, Yuli Y , Muiño-Mosquera, Laura , Guo, Dongchuan , Laughlin, Megan K., Ward, Colin R. , Michelena, Héctor I. , Bianco, Lisa , Yetman, Anji T., Bissell, Malenka M, Andreassi, Maria Grazia, Caffarelli, Anthony, Dongchuan, Guo, Tretter, Justin T., McBride, Kim L. , Investigators, EBAV

Mayo Clinic

Hearts | June 21, 2024 | Volume: 5 | Issue: 3 | Pages: 253-258

10.3390/hearts5030018 Get It

Bicuspid aortic valve (BAV) is the most common congenital heart malformation in adults, but it can also cause childhood-onset complications. The presentation and clinical course of young adults who present due to BAV complications are relatively uncharacterized. In a multicenter study, we found that young people who experience significant complications related to BAV disease before age 30 are distinguished from the majority of BAV cases that manifest after age 50 by a relatively severe clinical course, with higher rates of surgical interventions, more frequent second interventions, and a greater burden of congenital heart malformations. These observations highlight the need for prompt recognition, regular lifelong surveillance, and targeted interventions to address the significant health burdens of patients with early-onset BAV complications.
Predictors of Durable Remission After Successful Surgery for Cushing Disease: Results From the Multicenter RAPID Registry
Tenhoeve, Sam , Evans, James, Collopy, Sarah , Delery, William , Pacione, Donato , Silverstein, Julie , Gardner, Paul A. , Rotman, Lauren E., Yuen, Kevin C.J. , Barkhoudarian, Garni , Fernandez‐Miranda, Juan C. , Benjamin, Carolina , Kshettry, Varun R. , Zada, Gabriel , Catalino, Michael P. , Little, Andrew S. , Karsy, Michael , Van Gompel, Jamie, Karsy, Michael , Findlay, Matthew C. , Alt, Jeremiah A. , Rennert, Robert C , Couldwell, William T. , Evans, James, Kim, Won Bae , Kim, Albert H. , Chicoine, Michael , Gompel, Jamie J. Van

Mayo Clinic

Neurosurgery | June 21, 2024 | Volume: 95 | Issue: 4 | Pages: 761-769

10.1227/neu.0000000000003042 | PMID 39293794 Get It

BACKGROUND AND OBJECTIVE: Cushing disease (CD) affects mortality and quality of life along with limited long-term remission, underscoring the need to better identify recurrence risk. The identification of surgical or imaging predictors for CD remission after transsphenoidal surgery has yielded some inconsistent results and has been limited by single-center, single-surgeon, or meta-analyses studies. We sought to evaluate the multicenter Registry of Adenomas of the Pituitary and Related Disorders (RAPID) database of academic US pituitary centers to assess whether robust nonhormonal recurrence predictors could be elucidated. METHODS: Patients with treated CD from 2011 to 2023 were included. The perioperative and long-term characteristics of CD patients with and without recurrence were assessed using univariable and multivariable analyses. RESULTS: Of 383 patients with CD from 26 surgeons achieving postoperative remission, 288 (75.2%) maintained remission at last follow-up while 95 (24.8%) showed recurrence (median time to recurrence 9.99 ± 1.34 years). Patients with recurrence required longer postoperative hospital stays (5 ± 3 vs 4 ± 2 days, P = .002), had larger average tumor volumes (1.76 ± 2.53 cm 3 vs 0.49 ± 1.17 cm 3 , P = .0001), and more often previously failed prior treatment (31.1% vs 14.9%, P = .001) mostly being prior surgery. Multivariable hazard prediction models for tumor recurrence found younger age (odds ratio [OR] = 0.95, P = .002) and Knosp grade of 0 (OR = 0.09, reference Knosp grade 4, P = .03) to be protective against recurrence. Comparison of Knosp grade 0 to 2 vs 3 to 4 showed that lower grades had reduced risk of recurrence (OR = 0.27, P = .04). Other factors such as length of stay, surgeon experience, prior tumor treatment, and Knosp grades 1, 2, or 3 failed to reach levels of statistical significance in multivariable analysis. CONCLUSION: This multicenter study centers suggests that the strongest predictors of recurrence include tumor size/invasion and age. This insight can help with patient counseling and prognostication. Long-term follow-up is necessary for patients, and early treatment of small tumors may improve outcomes.
Intraocular Pressure Outcomes After Lampalizumab Injections in Patients With Geographic Atrophy
Bressler, Neil M. , Bakri, Sophie J. , Brittain, Christopher , Pickthorn, Karen, Lin, Hugh, Sun, Christy, Martin, Jillian , Freund, K. Bailey , Kim, Judy E. , Ferrara, Daniela , Pickthorn, Karen

Mayo Clinic

JAMA Ophthalmology | June 20, 2024 | Volume: 142 | Issue: 8 | Pages: 772

10.1001/jamaophthalmol.2024.2061 | PMID 38900484 Get It

ImportanceIntraocular pressure (IOP) elevations of clinical relevance have been observed after the commonly used 0.05-mL volume for intravitreous injections. However, more recently approved intravitreous agents involve volumes from 0.07 to 0.1 mL. It is not well established whether repeated 0.1-mL intravitreous injections may result in IOP-related complications.ObjectiveTo investigate the effect of 1 year of repeated 0.1-mL intravitreous injections on IOP outcomes.Design, Setting, and ParticipantsThis study was a post hoc analysis of 2 clinical trials investigating the IOP safety of intravitreous lampalizumab on geographic atrophy secondary to age-related macular degeneration. Both trials were conducted between 2014 and 2018 and recruited participants who were 50 years or older and had bilateral geographic atrophy. This post hoc analysis was performed between 2018 and 2022.InterventionsIntravitreous lampalizumab, 0.1 mL, every 4 weeks; lampalizumab, 0.1 mL, every 6 weeks; or sham procedure every 4 weeks or 6 weeks for 48 weeks.Main Outcomes and MeasuresIOP changes in the 4-week-frequency study arms and ocular adverse events to week 48 in all arms. The hypothesis for this analysis was formulated after data collection.ResultsAmong a total of 1851 participants, there was no change in mean pre-injection IOP values through 48 weeks in either arm. The adverse events glaucoma and ocular hypertension were reported for 1.8% of participants treated with lampalizumab and 1.6% of those in the sham arm.Conclusions and RelevanceOver 1 year, IOP increases were rare and did not affect treated participants more frequently than sham arm participants. These findings support the low risk of persistent IOP increases, on average, of intravitreous 0.1-mL injection volumes administered for 1 year in a manner similar to that performed in these clinical trials. These results may be valuable in the design of future therapeutic trials considering this volume for injections particularly as more recently approved agents use volumes of 0.07 to 0.1 mL.Trial RegistrationClinicalTrials.gov Identifiers: NCT02247479 and NCT02247531
Migraine headache in patients with spontaneous coronary artery dissection: A report of the iSCAD Registry
Wells, Bryan J. , O’Duffy, Anne E, Grodzinsky, Anna , Gornik, Heather L. , Kadian‐Dodov, Daniella , Hess, Connie N. , Sanghavi, Monika , Tam, Lori , Orford, James L., Vitarello, Clara, Alkhalfan, Fahad , Leon, Katherine K, Naderi, Sahar , Kim, Esther S.H. , Chi, Gerald , Gornik, Heather L , Kadian-Dodov, Daniella , Henkin, Stanislav , Alkhalfan, Fahad , Wood, Malissa J. , Sumner, Jennifer A. , Taylor, Angela, Henkin, Stanislav , Wells, Gretchen , Lindley, Kathryn J , Kumbhani, Dharam J. , Gibson, C. Michael , Leon, Katherine K.

Mayo Clinic

Vascular Medicine | June 20, 2024 | Volume: 29 | Issue: 3 | Pages: 286-295

10.1177/1358863x241252444 | PMID 38898631 Get It

Introduction: Spontaneous coronary artery dissection (SCAD) is a nonatherosclerotic cause of myocardial infarction. Migraine headache has been reported to be common among patients with SCAD, but the degree of migraine-related disability has not been quantified. Methods: Clinical data and headache variables were obtained from the baseline assessment of the prospective, multicenter iSCAD Registry. Migraine-related disability was quantified using the self-reported Migraine Disability Assessment (MIDAS). Demographic, clinical, psychosocial, and medical characteristics from data entry forms were compared between patients with and without migraine. Results: Of the 773 patients with available data, 46% reported previous or current migraines. Those with migraines were more likely to be women (96.9% vs 90.3%, p = 0.0003). The presence of underlying carotid fibromuscular dysplasia was associated with migraine (35% vs 27%, p = 0.0175). There was not a significant association with carotid artery dissection and migraine. Current migraine frequency was less than monthly (58%), monthly (24%), weekly (16%), and daily (3%). Triptan use was reported in 32.5% of patients, and 17.5% used daily migraine prophylactic medications. Using the MIDAS to quantify disability related to migraine, 60.2% reported little or no disability, 14.4% mild, 12.7% moderate, and 12.7% severe. The mean MIDAS score was 9.9 (mild to moderate disability). Patients with SCAD had higher rates of depression and anxiety (28.2% vs 17.7% [ p = 0.0004] and 35.3% vs 26.7% [ p = 0.0099], respectively). Conclusions: Migraines are common, frequent, and a source of disability in patients with SCAD. The association between female sex, anxiety, and depression may provide some insight for potential treatment modalities.
OTHR-20. MINIMALLY-INVASIVE MOLECULAR DIAGNOSIS OF INFILTRATING BRAINSTEM GLIOMAS THROUGH CEREBROSPINAL FLUID CELL-FREE DNA SEQUENCING
Hill, Katherine , Holle, Bridget M, Üçpınar, Burçin Ağrıdağ , DiNapoli, Sara , Riviere-Cazaux, Cécile , Burns, Terence, Haque, Sofia , Rosenblum, Marc K. , Doğan, Snjezana , Borsu, Laetitia , Ross, Dara S. , Zampieri, Caroline Barbosa, Donzelli, Maria, Lin, Andrew , Kramer, Kim , Souweidane, Mark M. , Arcila, Maria E. , Ladanyi, Marc , Mellinghoff, Ingo K. , Karajannis, Matthias A. , Miller, Alexandra , Mellinghoff, Ingo K , Karajannis, Matthias A , Vanderbilt, Chad , Giantini-Larsen, Alexandra , Hickman, Richard A. , Alano, Tina , Doe-Tetteh, Seyram A. , Young, Robert J. , Thakur, Sunitha B , Bale, Tejus , Benhamida, Jamal K. , Chang, Jason C. , Zampieri, Caroline Chaul de Lima Barbosa, Dunkel, Ira J. , Sait, Sameer Farouk , Greenfield, Jeffrey P. , Berger, Michael

Mayo Clinic

Neuro-Oncology | June 18, 2024 | Volume: 26 | Issue: Supplement_4 | Pages: 0-0

10.1093/neuonc/noae064.690 Get It

Abstract BACKGROUND Accurate molecular diagnosis of infiltrating brainstem tumors, including diffuse midline gliomas and IDH mutant astrocytomas, is essential for prognostication and optimal therapy. Surgical biopsy of the brainstem carries risk of permanent neurological deficits and may yield insufficient or non-diagnostic tissue. We hypothesized that minimally invasive “liquid biopsy” analyzing circulating tumor cell-free DNA (cfDNA) in cerebrospinal fluid (CSF) could represent an alternative molecular diagnostic modality. METHODS We performed MSK-IMPACT, a New York State Department of Health authorized hybridization capture-based next-generation panel DNA sequencing clinical assay on 44 CSF samples from 37 unique patients with brainstem tumors. Ages at time of CSF collection ranged from 1–47 years (median: 29 years). For samples in which diagnostic alterations could not be detected, we performed a series of secondary analyses for known hotspot mutations such as H3F3A, IDH1/2, and BRAF, including manual review for mutant reads below the official clinical reporting threshold, as well as droplet digital PCR (ddPCR). RESULTS Among 44 samples included in this study, 10/44 (23%) samples had mutations detected by MSK-IMPACT using standard clinical calling criteria and 14 of the remaining 34 samples (41%) had supporting evidence of a diagnostically relevant mutation based on manual review. Testing by ddPCR was performed on 11 samples (based on DNA availability), uncovering 4 additional mutations. Overall positive diagnostic yield was 64% (28/44). In biopsied patients, CSF confirmed disease-defining mutations in 80% (16/20) of CSF samples, including H3F3A K28M (9/10; 90%) and IDH1/2 (5/6; 83%). Among 24 unbiopsied patients, a disease-defining mutation was identified in 60% (15/25) of CSF samples. CONCLUSIONS Analysis of CSF cfDNA in patients with brainstem tumors has a high diagnostic yield and obviates the need for tissue biopsy in a majority of patients. A tiered testing approach using next-generation sequencing and ddPCR assays helps maximize diagnostic information and sensitivity.
A phase 1, open-label, dose escalation, and expansion study of CUE-102, a novel WT1-pHLA-IL2-Fc fusion protein, in patients with HLA-A*0201-positive disease and WT1-positive recurrent/metastatic cancers.
Uboha, Nataliya V. , Chaves, Jorge, Powderly, John D. , Gabrail, Nashat , Alistar, Angela , Chen, Christopher T. , Agensky, Laura, Goel, Apollina, Margossian, Steven, Quayle, Steven N., Levisetti, Matteo, Saenger, Yvonne M. , Alese, Olatunji B. , Kim, Dae Won , Zheng, Lei , Fu, Siqing , Gong, Jun , Jin, Zhaohui , Bekaii‐Saab, Tanios , Selfridge, Jennifer Eva

Mayo Clinic

Journal of Clinical Oncology | June 17, 2024 | Volume: 42 | Issue: 16_suppl | Pages: 3553-3553

10.1200/jco.2024.42.16_suppl.3553 Get It

3553 Background: Immuno-STATs are modular fusion proteins designed for the selective activation of tumor antigen specific CD8+ T cells. CUE-102, the second Immuno-STAT in clinical trials, is composed of a human leukocyte antigen (HLA) complex, HLA-A*0201, a peptide epitope derived from the Wilms Tumor 1 (WT1) protein, and 4 molecules of reduced affinity human interleukin-2 (IL-2). In preclinical studies CUE-102 binds, activates and expands WT1-specific CD8+ T cells with the potential to enhance anti-tumor immunity in patients with WT1+ cancers. Here we present the results of the dose-finding portion (Part A) of the CUE-102-01 study. Methods: CUE-102-01 is a 2 part phase 1 study. HLA-A*02:01 positive patients with WT1+ advanced colorectal (CRC), gastric (GA) and gastroesophageal junction (GEJ), pancreatic (PDAC) or ovarian (OvCa) tumors refractory to standard therapies were eligible for participation. WT1 status is determined by IHC via central testing. CUE-102 monotherapy was administered intravenously every three weeks in doses ranging from 1 mg/kg to 8 mg/kg following 3+3 design rules with a Bayesian Logistic Regression Model overlay. Dose levels that exhibit an immune or tumor response may be expanded to further characterize activity and toxicity as allowed by safety rules. Results: Dose escalation was successfully completed in 28 patients with CRC (17), PDAC (6), GA/GEJ (3) and OvCa (2). No DLTs were observed. Three dose levels (2, 4 and 8 mg/kg) exhibited evidence of immune activity and were expanded up to 9 patients each for further evaluation. CUE-102 was well-tolerated with > 96% of treatment-related adverse events (TRAEs) grade ≤2. The most common TRAEs, were fatigue, infusion reactions, nausea and vomiting. There were no cases of CRS Grade ≥ 2. Preliminary PK data demonstrate dose dependent increases in exposure across the dose range assessed. Preliminary analysis of patient samples demonstrates selective expansion of WT1-specific CD8+ T cells. Stable disease of ≥ 6 weeks (range 6-36 weeks), as determined by RECIST 1.1, has been observed in 10 of 23 patients (DCR 43.5%). Conclusions: CUE-102 is a novel T cell engager that demonstrates acceptable tolerability, favorable PK, and supportive preliminary PD readouts. No DLTs or drug-related SAEs have been observed in doses up to 8 mg/kg as of the data cut-off. Adverse events have been manageable and consistent with the CUE-102 mechanism of action and underlying disease. Early signs of disease stabilization and anti-tumor activity in late-stage patients are encouraging. Part B is a dose expansion that further evaluates safety, PK/PD, recommended phase 2 dose (RP2D), antitumor efficacy and is currently enrolling patients. Clinical trial information: NCT05360680 .